Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Total Debt
Short-term and long-term borrowings combined.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt remains negative
Q1 FY2026 total debt was $1.06M, compared with $0 a year earlier.
Context
- Total debt amounted to 9.7% of total assets at the end of Q1 FY2026, up 9.7 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 664.49K USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 664.49K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 total debt of $1.06M is the lowest of the 2 companies compared; the peer median is $7.43M.
- Total debt amounts to 9.7% of total assets for LIXT, versus a peer median of 24.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $7.43M | +46.2% | +14.4% | 24.1% | |
| Mar 2026 | $1.06M | — | — | 9.7% | |
| Peer median (excluding LIXT) | $7.43M | +46.2% | +14.4% | 24.1% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.